These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32418181)

  • 21. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
    Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R
    Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
    [No Abstract]   [Full Text] [Related]  

  • 23. Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.
    AlShoaibi NA; Maghrabi K; Alanazi H; Harbi MA; Alghamdi S
    Ann Saudi Med; 2020; 40(5):365-372. PubMed ID: 32954790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].
    Tomcsányi J; Tomcsányi K
    Orv Hetil; 2020 Apr; 161(17):689-691. PubMed ID: 32324363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
    Paliani U; Cardona A
    Eur J Intern Med; 2020 Aug; 78():1-3. PubMed ID: 32553587
    [No Abstract]   [Full Text] [Related]  

  • 26. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
    Gunay S; Caliskan S; Sigirli D; Sahin E
    Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
    Sapp JL; Alqarawi W; MacIntyre CJ; Tadros R; Steinberg C; Roberts JD; Laksman Z; Healey JS; Krahn AD
    Can J Cardiol; 2020 Jun; 36(6):948-951. PubMed ID: 32299753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
    Voisin O; Lorc'h EL; Mahé A; Azria P; Borie MF; Hubert S; Ménage E; Guillerm JC; Mourad JJ
    Mayo Clin Proc; 2020 Aug; 95(8):1696-1700. PubMed ID: 32753141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
    Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
    [No Abstract]   [Full Text] [Related]  

  • 30. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
    Jankelson L; Karam G; Becker ML; Chinitz LA; Tsai MC
    Heart Rhythm; 2020 Sep; 17(9):1472-1479. PubMed ID: 32438018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
    Ehrlich H; Elkbuli A
    Am J Emerg Med; 2021 Oct; 48():363-364. PubMed ID: 33551245
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
    Medeiros-Domingo A; Carrasco OF; Berni-Betancourt A
    Arch Cardiol Mex; 2020; 90(Supl):36-40. PubMed ID: 32523150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
    Szekely Y; Lichter Y; Shrkihe BA; Bruck H; Oster HS; Viskin S
    Heart Rhythm; 2020 Sep; 17(9):1452-1455. PubMed ID: 32380291
    [No Abstract]   [Full Text] [Related]  

  • 34. Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
    Stevenson A; Kirresh A; Conway S; White L; Ahmad M; Little C
    Open Heart; 2020 Aug; 7(2):. PubMed ID: 32817375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Shah RR
    J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
    Chotsiri P; Tarning J; Hoglund RM; Watson JA; White NJ
    Clin Pharmacol Ther; 2022 Oct; 112(4):824-835. PubMed ID: 35598114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
    Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?
    Schluenz LA; Ramos-Otero GP; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):266-271. PubMed ID: 32769401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.